Dashboard
Manage Tickers

CDNA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

caredx-launches-histomap-kidney-a-tissue-based-gene-expression-test-advancing-precision-diagnosis-in-kidney-transplant-rejection
CareDx Launches HistoMap Kidney, A Tissue-...
11/06/2025 13:05:58

CareDx Extends Leadership in Kidney Transplant Molecular Testing with Launch of Unique Tissue-Based Gene Expression Assay – His...

3-analysts-have-this-to-say-about-caredx
3 Analysts Have This To Say About CareDx
11/06/2025 11:45:01

btig-maintains-buy-on-caredx-raises-price-target-to-25
BTIG Maintains Buy on CareDx, Raises Price...
11/06/2025 09:49:18

BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $22 to $25.

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
11/05/2025 12:05:48

caredx-raises-fy2025-sales-guidance-from-367000m-373000m-to-372000m-376000m-vs-368883m-est
CareDx Raises FY2025 Sales Guidance from $...
11/04/2025 21:06:48

CareDx (NASDAQ:CDNA) raises FY2025 sales outlook from $367.000 million-$373.000 million to $372.000 million-$376.000 million vs...

caredx-q3-adj-eps-028-beats-014-estimate-sales-100055m-beat-95251m-estimate
CareDx Q3 Adj. EPS $0.28 Beats $0.14 Estim...
11/04/2025 21:06:26

CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.14 by 97.18...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

caredx-announces-publication-of-the-second-study-from-surveillance-heartcare-outcomes-registry-in-the-journal-of-the-american-college-of-cardiology-second-shore-study-validates-allosure-heart-an-integral-component-of-heartcare-as-a-reliable-biomarker-for-antibody-mediated-rejection-in-heart-transplant-recipients
CareDx Announces Publication Of The Second...
10/23/2025 20:18:57

a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated,...

caredx-to-feature-new-ivd-products-and-ivdr-certification-for-alloseq-tx-and-qtype-at-ashi-2025-annual-meeting
CareDx To Feature New IVD Products And IVD...
10/06/2025 11:12:34

Furthers Global Leadership in Donor Organ and Transplant Recipient HLA TypingCareDx, Inc. (NASDAQ:CDNA) – The Transplant Compan...

4-analysts-assess-caredx-what-you-need-to-know
4 Analysts Assess CareDx: What You Need To...
09/23/2025 14:02:11

btig-reiterates-buy-on-caredx-maintains-22-price-target
BTIG Reiterates Buy on CareDx, Maintains $...
09/23/2025 09:56:52

BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.

btig-reiterates-buy-on-caredx-maintains-22-price-target
BTIG Reiterates Buy on CareDx, Maintains $...
09/12/2025 10:33:46

BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.

caredx-urges-noridian-to-preserve-coverage-for-combination-and-personalized-molecular-testing-opposes-surveillance-limits-and-bundled-payments-in-draft-lcd-dl40060
CareDx Urges Noridian To Preserve Coverage...
09/02/2025 20:05:21

CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, developme...

caredx-submits-comment-letter-on-draft--local-coverage-determination-policy
CareDx Submits Comment Letter On Draft Lo...
09/02/2025 20:03:53

caredx-battles-reimbursement-uncertainty-as-market-overlooks-long-term-potential
CareDx Battles Reimbursement Uncertainty A...
08/26/2025 17:08:11

CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant so...

this-actuate-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-tuesday
This Actuate Therapeutics Analyst Begins C...
08/26/2025 11:49:01

william-blair-initiates-coverage-on-caredx-with-market-perform-rating
William Blair Initiates Coverage On CareDx...
08/26/2025 11:32:23

William Blair analyst Andrew Brackmann initiates coverage on CareDx (NASDAQ:CDNA) with a Market Perform rating.

wells-fargo-maintains-equal-weight-on-caredx-lowers-price-target-to-14
Wells Fargo Maintains Equal-Weight on Care...
08/08/2025 15:24:20

Wells Fargo analyst Brandon Couillard maintains CareDx (NASDAQ:CDNA) with a Equal-Weight and lowers the price target from $1...

caredx-names-nathan-smith-as-cfo
CareDx Names Nathan Smith As CFO
08/06/2025 21:10:25

caredx-narrows-fy2025-sales-guidance-from-365000m-375000m-to-367000m-373000m-vs-370794m-est
CareDx Narrows FY2025 Sales Guidance from ...
08/06/2025 20:37:05

CareDx (NASDAQ:CDNA) narrows FY2025 sales outlook from $365.000 million-$375.000 million to $367.000 million-$373.000 million v...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION